XML 89 R78.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 3,812 | $ 3,707 | $ 7,404 | $ 7,220
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,797 | 1,750 | 3,456 | 3,417
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,015 | 1,957 | 3,948 | 3,803
Operating Segments | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,322 | 1,276 | 2,551 | 2,433
Operating Segments | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 748 | 743 | 1,415 | 1,474
Operating Segments | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 602 | 550 | 1,180 | 1,073
Operating Segments | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,118 | 1,116 | 2,220 | 2,188
Operating Segments | United States | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 729 | 720 | 1,402 | 1,378
Operating Segments | United States | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 550 | 538 | 1,023 | 1,057
Operating Segments | United States | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 197 | 182 | 388 | 355
Operating Segments | United States | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 305 | 294 | 616 | 587
Operating Segments | International | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 593 | 556 | 1,149 | 1,055
Operating Segments | International | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 198 | 205 | 392 | 417
Operating Segments | International | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 405 | 368 | 792 | 718
Operating Segments | International | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 813 | 822 | 1,604 | 1,601
Operating Segments | Infusion Therapies and Technologies | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,045 | 1,004 | 2,011 | 1,915
Operating Segments | Infusion Therapies and Technologies | United States | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 579 | 570 | 1,105 | 1,084
Operating Segments | Infusion Therapies and Technologies | International | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 466 | 434 | 906 | 831
Operating Segments | Advanced Surgery | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 277 | 272 | 540 | 518
Operating Segments | Advanced Surgery | United States | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 150 | 150 | 297 | 294
Operating Segments | Advanced Surgery | International | Medical Products and Therapies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 127 | 122 | 243 | 224
Operating Segments | Care and Connectivity Solutions | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 452 | 436 | 854 | 865
Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 332 | 311 | 610 | 609
Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 120 | 125 | 244 | 256
Operating Segments | Front Line Care | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 296 | 307 | 561 | 609
Operating Segments | Front Line Care | United States | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 218 | 227 | 413 | 448
Operating Segments | Front Line Care | International | Healthcare Systems and Technologies |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 78 | 80 | 148 | 161
Operating Segments | Injectables and Anesthesia | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 341 | 332 | 669 | 637
Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 197 | 182 | 388 | 355
Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 144 | 150 | 281 | 282
Operating Segments | Drug Compounding | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 261 | 218 | 511 | 436
Operating Segments | Drug Compounding | United States | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | Drug Compounding | International | Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 261 | 218 | 511 | 436
Operating Segments | Chronic Renal | Revision of Prior Period, Reclassification, Adjustment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales |  | (8) |  | (16)
Operating Segments | Chronic Renal | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 917 | 928 | 1,805 | 1,812
Operating Segments | Chronic Renal | United States | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 228 | 230 | 454 | 459
Operating Segments | Chronic Renal | International | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 689 | 698 | 1,351 | 1,353
Operating Segments | Acute Therapies | Revision of Prior Period, Reclassification, Adjustment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales |  | 8 |  | 16
Operating Segments | Acute Therapies | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 201 | 188 | 415 | 376
Operating Segments | Acute Therapies | United States | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 77 | 64 | 162 | 128
Operating Segments | Acute Therapies | International | Kidney Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 124 | 124 | 253 | 248
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 22 | 22 | 38 | 52
Other | United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 16 | 16 | 27 | 40
Other | International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 6 | $ 6 | $ 11 | $ 12

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_KidneyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InfusionTherapiesAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_CareAndConnectivitySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InjectablesAndAnesthesiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PharmaceuticalCompoundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_ChronicRenalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AcuteTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |